Has ICMR Opened EoIs for Tech Transfer of Chikungunya Antibody Detection Kit?
Click to start listening
Synopsis
The ICMR has taken a significant step by inviting EoIs for the tech transfer of the IgM ELISA kit for Chikungunya detection. This initiative aims to enhance early diagnosis and response to the rising Chikungunya outbreaks, especially in tropical regions. The kit's proven efficacy makes it a critical tool in public health.
Key Takeaways
- ICMR invites EoIs for the IgM ELISA Kit.
- The kit aids in early detection of Chikungunya.
- High diagnostic sensitivity and specificity.
- Significant market potential in tropical regions.
- Focus on decentralised testing enhances public health response.
New Delhi, July 21 (NationPress) The Indian Council of Medical Research (ICMR) is calling for expressions of interest (EoI) from qualified companies and manufacturers to facilitate the technology transfer for the commercialization of the IgM ELISA Kit designed for Chikungunya detection, a disease transmitted by vectors.
The IgM-based diagnostic ELISA kit for identifying the Chikungunya virus has been developed by the ICMR-National Institute of Virology. It is intended to assist in detecting Chikungunya virus-specific IgM antibodies in patient serum, which is crucial for early diagnosis in individuals showing symptoms associated with this infection.
According to the ICMR, ICMR-Medical Innovations Patent Mitra is offering its validated Chikungunya IgM ELISA Kit for technology transfer and commercialization. This kit is crafted for early-stage detection, cost-effective, and scalable. The technology has been independently validated and is also utilized in the National Vector Borne Disease Control Programme.
The EoI states that “it is currently in regular production and the kits are being supplied to sentinel surveillance hospitals and apex referral laboratories under the national program.”
This kit has been evaluated by the US Centers for Disease Control (CDC) and boasts a diagnostic sensitivity of 95 percent and diagnostic specificity of 98 percent. It also exhibits excellent inter- and intra-assay reproducibility, as per the EoI.
IgM antibodies are essential for early-stage detection, rendering these kits invaluable for timely diagnosis and containment of the virus, prevalent across the globe.
The EoI highlights that the IgM-based Diagnostic ELISA kit for detecting the Chikungunya virus holds significant market potential spurred by the rising prevalence of Chikungunya outbreaks in tropical and subtropical regions, notably in Asia, Africa, and Latin America.
As governments and healthcare providers focus on early detection and decentralized testing, IgM ELISA kits offer both clinical relevance and commercial viability.
Chikungunya is a viral disease transmitted by mosquitoes, caused by an Alphavirus from the Togaviridae family, first identified in Tanzania in 1953, and has triggered multiple outbreaks in tropical areas of Africa and South Asia.
Common symptoms include fever, joint pain, headache, muscle pain, joint swelling, and rash.
Currently, there are no antiviral treatments available for chikungunya.
Point of View
It is vital to recognize the significance of the ICMR's initiative in enhancing public health responses to vector-borne diseases. The focus on early detection through advanced technology is a proactive approach that aligns with national health priorities. This development not only addresses immediate health concerns but also fosters innovation in diagnostics.
NationPress
05/09/2025
Frequently Asked Questions
What is the IgM ELISA Kit?
The IgM ELISA Kit is a diagnostic tool developed by the ICMR to detect IgM antibodies specific to the Chikungunya virus in patient serum, aiding in early diagnosis.
What is the significance of the EoI issued by ICMR?
The EoI invites eligible companies to transfer technology for the commercialization of the IgM ELISA Kit, addressing the need for effective diagnostic solutions for Chikungunya.
How effective is the IgM ELISA Kit?
The kit has shown a diagnostic sensitivity of 95% and specificity of 98%, making it a reliable tool for detecting Chikungunya.
Where is the IgM ELISA Kit being used?
The kit is currently in regular production and is supplied to sentinel surveillance hospitals and apex referral laboratories under the national program.
What are the symptoms of Chikungunya?
Symptoms include fever, joint pain, headache, muscle pain, joint swelling, and rash.
